Practice Management News

The AMA approved multiple opioid-related policies at their annual meeting that aim to make patients the focus of pain treatment rather than third party controls that create treatment barriers.

Legalization of medical cannabis did not reduce the rate of opioid overdose deaths, according to a report recently published in the Proceedings of the National Academy of Sciences.

A tool that researchers dubbed the “patient-report adverse drug event instrument” only identified adverse drug events in older patients in certain situations, according to findings published in Annals of Family Medicine.

In this guest commentary, Austin Chiang, MD, MPH, director of the e ndoscopic bariatric program and chief medical social media officer at Jefferson Health in Philadelphia, discusses his latest role as President and founding member of the newly established Association for Healthcare Social Media. Chiang shares the ongoing vision for the organization in addition to the reason for its conception and goals.

The health care diagnostics company LabCorp announced that “unauthorized activity” occurred on the webpage of American Medical Collection Agency, LabCorp’s external collection agency, impacting up to 7.7 million patients.

Galantamine may also someday help treat opioid addiction, according to results published in The American Journal on Addictions.

The idea of importing prescription drugs from Canada as a means to lower prices is back under scrutiny with President Donald J. Trump verbally supporting several state laws that would allow such actions, mainstream media reported.

About 100 people provided an FDA panel with study data, real-life anecdotes or proposed ideas, as it establishes regulatory framework for cannabidiol, or CBD, at a public hearing on Friday.

HHS recently enacted one of the first concrete steps toward President Donald J. Trump’s pledge to lower drug prices in finalizing a federal rule requiring the list prices of certain drugs be included in television ads.

The FDA is scheduled to hold a hearing Friday, May 31, that seeks to help broaden the agency’s knowledge and help clear up the public’s uncertainty about cannabidiol, or CBD, according to a press release.